会社概要
- 正式社名: Viwit Pharmaceutical Co., Ltd.
- 国際名称: 维威制药 (Viwit Pharmaceutical Co., Ltd.), China
- ブランド名 / 商号: Viwit
- 登録国: China
説明:
Viwit Pharmaceutical Co., Ltd., established in 2006, manufactures pharmaceutical intermediates and active pharmaceutical ingredients with a particular specialization in borane- and boron-based reducing reagents, including borane-dimethyl sulfide, borane-THF, borane-pyridine, and various borane-amine complexes, alongside chiral pyrrolidine, piperidine, and indanyl building blocks. Its finished API portfolio includes aprepitant and fosaprepitant dimeglumine, varenicline tartrate, luliconazole, vildagliptin, and the MRI contrast agents gadobutrol monohydrate and gadolinium meglumine. The company offers CRO, CMO, and CDMO contract manufacturing under OEM, ODM, and own-brand arrangements, and sells across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa.
事業活動
健康食品・機能性食品
サプライヤー
完成医薬品(製剤)
製造業者
バイオ医薬品
バイオテクノロジー・バイオ医薬品企業
原薬(API)
製造業者
医薬用化学品
製造業者
ATC分類(解剖治療化学分類)
製造業者
販売市場
- Western Europe: Austria, Belgium, France
- Northern America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States
- Central America: Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama
- South America: Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Falkland Islands, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela
主要製品/サービス
- 原薬(API): Gadobutrol monohydrate, Aprepitant, Lifitegrast, Varenicline Tartrate, EFINACONAZOLE, Fosaprepitant dimeglumine, Gadolinium meglumine, Luliconazole, Miraberon
- 受託・アウトソーシングサービス: Product Development
- 完成医薬品(製剤): Finished antibiotic medicines
- 医薬用化学品: (+)-B-Chlorodiisopinocampheylborane, Catecholborane, (R)-(+)-2-(Diphenylhydroxymethyl)pyrrolidine, (S)-(-)-2-(Diphenylhydroxymethyl)pyrrolidine, Borane tetrahydrofuran complex, (R)-(5-Cyano-2, 3-dihydro-1H-inden-1-yl) carbamic acid tert-butyl ester, (R)-tert-Butyl (5-bromo-2, 3-dihydro-1H-inden-1-yl) carbamate(R)-TERT-BUTYL (5-BROMO-2,3-DIHYDRO-1H-INDEN-1-YL)CARBAMATE, (R)-1-Amino -2, 3-dihydro-1H-indene-5-carbonitrile hydrochloride, 1-Methyl-6-boronic acid pinacolyl ester-3,4-dihydroquinoline -2(1H)-one, (1S,2S,3R,5S)-(+)-2,3-Pinanediol, 1-(2-Tetrahydropyranyl)-1H-pyrazole-5-boronic acid ester, 1-(((2R,3S)-2-(2,4-difluorophenyl)-3-methylepoxyethyl-2-yl) methyl)-1H-1,2,4-triazole, 1-BOC-3, 3-Dimethyl-4-oxopiperidine, 1-HYDROXYETHYL ADAMANTANE, [1,1 '-Biphenyl]-4-yl [4-[[1,1'-biphenyl]-4-sulfanyl] phenyl] thioninium-tetrakis (pentafluorophenyl) borate, 1,1-Dimethylethyl 4-hydroxy-4-[(2-methoxyethoxy)methyl]-1-piperidinecarboxylate, 1,2-Bis [(trifluorovinyl) oxy] ethane, 1H-indazole -7-carboxylic acid methyl ester, 1H-indazole-7-carboxamide, (1R,2R,3S,5R)-(-)-2,3-Pinanediol, 2 - methyl -5-- nitroimidazole, 2 '-fluoro -1,1': 4 ', 1'-terphenyl, 2-((1R)-1-AMINOETHYL)-4-FLUOROPHENOL, 2-(2-Amino-5-bromo-benzoyl) pyridine, 2-Chloro-1, 3,2-dioxaphosphine, 2-Chloro-3-fluorophenylboronic acid, 2-Fluoro-6-hydroxyphenylboronic acid pinacol ester, ((2-Fluoro-8-(4,4, 5,5-tetramethyl -1,3, 2-dioxaborolan-2-yl) naphthalen-1-yl) ethynyl) triisopropylsilane, 2-Methylpyridine-N-borane, (2R,3R)-2-(2,4-Difluorophenyl)-1-(1H-1, 2,4-triazol-1-yl) butane-2, 3-diol, (2R,3S)-2-[(1R)-1-[3,5-bis (trifluoromethyl) phenyl] ethoxy]-3-(4-fluorophenyl)-morpholine hydrochloride(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)Morpholine hydrochloride, (2R,3S)-2-[(1R)-1-[3,5-bis (trifluoromethyl) phenyl] ethoxy]-3-(4-fluorophenyl) morpholine p-benzenesulfonate, (3-(9-borabicyclo[3.3.1]nonan-9-yl)propyl)triphenylphosphoniumebromide, 3-acetamidopyrazole, 3-Chloro-5-hydroxybenzonitrile, 3-Fluoro-5-hydroxybenzonitrile, 3-fluoroquinoline -5-borate pinacol ester, 3,5-Difluorobenzonitrile, 4-Bromo-2-fluorobiphenyl, 4-Cyano -1-(2,6-difluorobenzyl)-1H-1,2,3-triazole, 4-Methanesulfonyl-cyclohexyl ketone, 4-Methylene Piperidine Hydrochloride, 5-Bromo-3-fluoroquinoline, 5-chloromethyl-2, 4-dihydro [1,2,4] triazol-3-one, 5-ethyl -2-methyl pyridine borane, 6-Bromo-3-iodo-1-methyl-1H-indazole, 6,6-Dimethyl-3-azabicyclo [3.1.0] hexane-2, 4-dione, 6,6-Dimethyl-3-azabicyclo [3.1.0] hexane, 7-Carboxyl -1H-indazole, 7-Hydroxy-[1,2,4] triazolo [1,5-A] pyridine, 9-Borabicyclo[3.3.1]nonane, Borane-2-picoline complex, Borane-ammonia, borane diethylamine complex, Borane-dimethyl sulfide complex intermediates, Borane-dimethylamine, Borane-N,N-diisopropylethylamine, Borane-pyridine, Borane-tert-butylamine complex, borane triethylamine complex, borane trimethylamine complex, cis-1-BOC-3, 4-dihydroxypyrrolidine, Cis-1-BOC-3-hydroxy-4-methoxypyrrolidine, cis-1-BOC-pyrrolidine-3, 4-diamine, cis-3, 4-dihydroxypyrrolidine hydrochloride, Decafluoro-3-methoxy-2-trifluoromethylpentane, Diethyl (3-Pyridyl) Borane, DOTA intermediates, ethyl 2-acetyl acetate chloride, Ethyl 3-(2-chlorophenoxy)-2-butenoate, FOMC-Glutamic acid -5-methyl ester, Glyoxal -1,1-dimethyl acetal, imidazole -1-yl acetonitrile, Indolo [2,3-A] carbazole, Methyl (3S)-7-bromo-2, 3-dihydro-2-oxo-5-(2-pyridyl)-1H-1, 4-benzodiazepine -3-propionate, Methylboronic acid, N-BOC-Amino-piperidinyl -1,1-carboxylic acid, N-Methyl morpholine borane, N-tert-butyl-1H-indazole-7-carboxamide, N,N-Diethylaniline Borane intermediates, N,N-dihexadecylphenylammonium tetrakis (pentafluorophenyl) borateN,N-dihexadecylanilinium tetrakis(pentafluorophenyl)borate, N,N-Dimethylanilinium tetrakis (pentafluorophenyl) borate, N,N-dioctadecylmethylammonium tetrakis(pentafluorophenyl)borate, Pinacolborane intermediates, Potassium tetrakis (pentafluorophenyl) borate, Propylgallate Injection, Pyridine-2-sulfonyl fluoride, (R)-( )-1-Phenylethanol, (R)-3-(Methoxymethyl) pyrrolidine -1-carboxylic acid ((3S,7aS)-7a-hydroxymethyl-6-(methylene) tetrahydro1H-pyrrorizin-3-yl) methanol ester, (R)-Methyl Oxazaborolidine intermediates, (S)-(-)-1-Phenylethanol, (S)-(-)-1,2, 3,4-tetrahydro-1-naphthoic acid, (S)-2-Amino-5-methoxytetrahydronaphthalene (S)-mandelate, (S)-2-Chloro-1-(2,4-dichlorophenyl), (S)-2-Chloro-1-(2,4-dichlorophenyl) ethyl methanesulfonate, (S)-3-Amino -3-(4-chlorophenyl)-propionic acid, (S)-Methyl Oxazaborolidine intermediates, Sodium tetrakis (pentafluorophenyl) borate, tert-Butyl 1-oxo-6-azospiro [2.5] octane -6-carboxylate, tert-Butyl 2-((4R,6R)-6-(2-(4-fluorophenyl)-4-((4-(hydroxymethyl) phenyl) carbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl) ethyl)-2,2-dimethyl-1,3-diox-4-yl) acetate, tert-Butyl 3,3-dimethyl -4-(((trifluoromethyl) sulfonyl) oxy)-3,6-dihydropyridine -1(2H)-carboxylatetert-Butyl 3,3-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate, tert-Butyl (3S)-3-(4-bromophenyl) piperidine-1-carboxylatetert-butyl (S)-3-(4-bromophenyl)piperidine-1-carboxylate, tert-Butyl trans-(3R,4R)-3,4-diaminopyrrolidine-1-carboxylate, tert-Butyl trans-(3S,4S)-3,4-diaminopyrrolidine-1-carboxylate, Tetrabenzyl pyrophosphate, Triethylboron -1,3-propanediamine, Triethylboron -1,6-hexanediamine, Trimethylboroxine, Triphenylcarbon tetrakis (pentafluorophenyl) borate
- ATC分類(解剖治療化学分類): Vildagliptin, Aceglutamide Injection
当社の製品・サービス
Sell · Pharma Chemicals
Sell · Laboratory Chemicals, Solvents & Reference Standards
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Pharma Chemicals
Sell · Pharma Chemicals
Sell · Pharma Chemicals
Sell · Pharma Chemicals
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · ATC (Anatomical Therapeutic Chemical) Classification
認証
評価
(0)
(0)
(0)
(0)
(0)
コメント
フィルター:
並べ替え:
コメントはありません。
評価とコメントを残す